Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 12/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531104 | 0.85 | ERN1 (0.65) | ERN1 | |
| SCHEMBL14849044 | 0.85 | ERN1 (0.49) | ERN1CDK1MAPTTRIM24TRIM33 | |
| SCHEMBL12072122 | 0.85 | ERN1 (0.48) | ERN1CDK1MAPTTRIM24TRIM33 | |
| SCHEMBL537374 | 0.84 | POLB (0.56) | ERN1MEN1KMT2ANQO2POLB | |
| SCHEMBL13257343 | 0.83 | ERN1 (0.55) | ERN1CDK1MAPTTRIM24TRIM33 | |
| SCHEMBL26425918 | 0.83 | NQO2 (0.68) | ERN1NQO2 | |
| SCHEMBL2149402 | 0.82 | ERN1 (0.46) | ERN1CDK1MAPTTRIM24TRIM33 | |
| SCHEMBL3648582 | 0.82 | ERN1 (0.46) | ERN1CDK1MAPTTRIM24TRIM33 | |
| SCHEMBL6853258 | 0.81 | POLB (0.42) | MEN1KMT2APOLBMAPT | |
| SCHEMBL332380 | 0.80 | MAPT (0.62) | ERN1MEN1KMT2ACDK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661416-A | Small molecular probe and preparation method and application thereof | 上海师范大学 | 2025-03-21 | — | — | CN | claimed |
| CN-122080106-A | Oleanolic acid acylhydrazone derivative and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250382303-A1 | NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-12-18 | — | — | US | disclosed |
| US-20250326777-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4619097-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4605374-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | Hepaitech (Beijing) Biopharma Technology Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| CN-120129676-A | Compounds, compositions, and methods thereof | 海湃泰克(北京)生物医药科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-12325715-B2 | Fluorous metal chelates compositions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-10 | — | — | US | disclosed |
| US-6136825-A | ANTIDEPRESSANTS AND CENTRAL NERVOUS SYSTEM AGENTS | KNOLL AKTIENGESELLSCHAFT | 2000-10-24 | — | — | US | disclosed |
| CN-1257489-A | Substituted benzopyran derivatives for the treatment of inflammation | SEARLE & CO (US) | 2000-06-21 | — | — | CN | disclosed |
| CN-1247537-A | Sulfonamide compounds having 5-HT receptor activity | KNOLL AG (DE) | 2000-03-15 | — | — | CN | disclosed |
| WO-1999062902-A1 | N-BENZODIOXANYLMETHYL-1-PIPERIDYL-METHYLAMINE COMPOUNDS HAVING AFFINITY FOR 5-HT RECEPTORS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-12-09 | — | — | WO | disclosed |
| EP-0958279-A1 | CATALYST COMPOSITIONS AND PROCESSES FOR OLEFIN POLYMERS AND COPOLYMERS | Cryovac, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| EP-0948498-A1 | SULFONAMIDE COMPOUNDS HAVING 5-HT RECEPTOR ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998042664-A1 | CATALYST COMPOSITIONS AND PROCESSES FOR OLEFIN POLYMERS AND COPOLYMERS | CRYOVAC, INC. (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998029411-A1 | SULFONAMIDE COMPOUNDS HAVING 5-HT RECEPTOR ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-09 | — | — | WO | disclosed |
| US-4600719-A | Tetrahydropyridine and piperidine derivatives | CIBA GEIGY CORPORATION (US) | 1986-07-15 | — | — | US | disclosed |
| US-4210655-A | Anti-depressant benzofuranyl piperidines | CIBA-GEIGY CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | ERN1 1112/4885MEN1 730/4885KMT2A 67/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | ERN1 1469/4885MEN1 406/4885KMT2A 52/4885 |
| US-12325715-B2 | Fluorous metal chelates compositions | KAT6A, SLC6A12, SLC6A6 | ERN1 3570/4885MEN1 269/4885KMT2A 630/4885 |
| US-20250326777-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | MRGPRX4, MRGPRX1, MRGPRX2 | ERN1 3115/4885MEN1 1133/4885KMT2A 2511/4885 |
| US-20250382303-A1 | NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CYBB, NOX4, NOX1 | ERN1 2705/4885MEN1 4759/4885KMT2A 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.